Πλοήγηση ανά Θέμα "VIRUS INFECTION"

Αποτελέσματα 1-3 από 3

Entecavir monotherapy for lamivudine-refractory chronic hepatitis B

Goulis, I.; Dalekos, G. N. (2008)

Evaluation of: Sherman M, Yurdaidin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical and serology outcomes through 96 weeks. Hepatology 48, 99-108 (2008). ...
Hepatitis B re-activation with rituximab therapy: treat the patient not the disease

Zachou, K.; Dalekos, G. N. (2011)
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

Papatheodoridis, G. V.; Dalekos, G. N.; Yurdaydin, C.; Buti, M.; Goulis, J.; Arends, P.; Sypsa, V.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Papaioannou, C.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L. A.; Lampertico, P. (2015)

Background & Aims: The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We evaluated the incidence and predictors of ...